Phase 2 Clinical Trial Data Of UF-021 In Retinitis Pigmentosa Patients Presented At ARVO 2011

Sucampo Pharmaceuticals, Inc. ("Sucampo"), (NASDAQ: SCMP) today reported data from a proof of concept phase 2 clinical trial conducted by R-Tech Ueno, Ltd. ("RTU", JASDAQ: 4573), of UF-021 (unoprostone isopropyl) in 112 patients with retinitis pigmentosa (RP)...

Full Story →